Estrogen receptor β selective ligands: Discovery and SAR of novel heterocyclic ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 24, 2005, Pages 5562-5566

  Chesworth, Richard ^a,b   Wessel, Matthew D ^a   Heyden, Lisa ^a   Mangano, F Michael ^a   Zawistoski, Michael ^a   Gegnas, Laura ^a   Galluzzo, David ^a   Lefker, Bruce ^a   Cameron, Kimberly O ^a   Tickner, Jeanne ^a   Lu, Bihong ^a   Castleberry, Tessa A ^a   Petersen, Donna N ^a   Brault, Amy ^a   Perry, Pia ^a   Ng, Oicheng ^a   Owen, Thomas A ^a   Pan, Lydia ^a   Ke, Hua Zhu ^a   Brown, Thomas A ^a   Thompson, David D ^a   DaSilva Jardine, Paul ^a   more..

^a PFIZER INC   (United States)

^b EnVivo Pharmaceuticals   (United States)

Author keywords

ER beta selective ligands; Estrogen receptor

Indexed keywords

ANILINE DERIVATIVE; BENZENE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; HETEROCYCLIC COMPOUND; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; L 384M; LIGAND; M 421I; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HETEROCYCLIC COMPOUNDS; HUMANS; INDICATORS AND REAGENTS; KINETICS; LIGANDS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 27644480409     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.08.010     Document Type: Article

References (35)

1. D.J. Manglesdorf, C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon, and R.M. Evans Cell 83 1995 835
2. A. Nasr, and M. Breckwoldt Gynecol. Endocrinol. 12 1998 43
3. U. Ulmsten Proc. Soc. Exp. Biol. Med. 217 1998 2
4. J.A. Cauley, S.R. Cummings, D.M. Black, S.R. Mascioli, and D.G.D. Seeley Am. J. Obstet. Gynecol. 163 1990 438
5. J.A. Scott, C.C. Da Camara, and J.E. Early Am. Fam. Physician 60 1999 1131
6. C. Miller Curr. Pharm. Des. 8 2002 2089
7. G.C. Kuiper, B. Carlsson, E. Enmark, Pelto-Huikko, S. Nilsson, and J.Å. Gustafsson Proc. Natl. Acad. Sci. U.S.A. 93 1996 5925
8. S. Mosselmann, J. Polman, and R. Dijkema FEBS Lett. 392 1996 49
9. G.C. Kuiper, B. Carlsson, K. Grandien, E. Enmark, J. Haggblad, S. Nilsson, and J.Å. Gustafsson Endocrinology 138 1997 863
10. J.F. Couse, J. Lindzey, K. Grandien, J.Å. Gustafsson, and K.S. Korach Endocrinology 138 1997 4613
11. B.S. Katzenellenbogen, and K.S. Korach Endocrinology 138 1997 861
12. P.J. Shughrue, B. Komm, and I. Merchenthaler Steroids 61 1996 678
13. L. Wang, S. Andersson, M. Warner, and J.Å. Gustafsson Proc. Natl. Acad. Sci. U.S.A. 98 2001 2792
14. G.B. Tremblay, A. Trembaly, N.G. Copeland, D.J. Gilbert, N.A. Jenkins, F. Labrie, and V. Giguere Mol. Endocrinol. 11 1997 353
15. Wessel, M. Unpublished data.
16. A.C.W. Pike, A.M. Brzozowski, R.E. Hubbard, T. Bonn, A.G. Thorsell, O. Engstrom, J. Ljunggren, J.Å. Gustafsson, and M. Carlquist EMBO 18 1999 4608
17. A.M. Brzozowski, A.C. Pike, Z. Dauter, R.E. Hubbard, T. Bonn, O. Engstrom, L. Ohman, G.L. Greene, and J.Å. Gustafsson Nature 389 1997 753
18. R. Chesworth, M.P. Zawistoski, B.A. Lefker, K.O. Cameron, R.F. Day, F.M. Mangano, R.L. Rosati, S. Colella, D.N. Petersen, A. Brault, B. Lu, L.C. Pan, P. Perry, O. Ng, T.A. Castleberry, T.A. Owen, T.A. Brown, D.D. Thompson, and P. DaSilva-Jardine Bioorg. Med. Chem. Lett. 14 2004 2729
19. J. Renaud, S.F. Bischoff, T. Buhl, P. Floersheim, B. Fournier, C. Halleux, J. Kallen, H. Keller, J.M. Schlaeppi, and W. Stark J. Med. Chem. 46 2003 2945
20. M.J. Meyers, J. Sun, K.E. Carlson, B.S. Katzenellenbogen, and J.A. Katzenellenbogen J. Med. Chem. 42 1999 2456
21. M.J. Meyers, J. Sun, K.E. Carlson, G.A. Marriner, B.S. Katzenellenbogen, and J.A. Katzenellenbogen J. Med. Chem. 44 2001 4230
22. U. Schopfer, P. Schoeffter, S.F. Bischoff, J. Nozulak, D. Feuerbach, and P. Floersheim J. Med. Chem. 45 2002 1399
23. B.R. Henke, T.G. Consler, N. Go, R.L. Hale, and D.R. Hohman J. Med. Chem. 45 2002 5492
24. H.A. Harris, L.M. Albert, Y. Leathbury, M.S. Malamas, R.E. Mewshaw, C.P. Miller, Y.P. Kharode, J. Marzolf, B.S. Komm, R.C. Winneker, D.E. Frail, R.A. Henderson, Y. Zhu, and J.C. Keith Jr. Endocrinology 144 2003 4241
25. J.G. Lombardino, and E.H. Wiseman J. Med. Chem. 17 1974 1182
26. R.N. Iyer, and R. Gopalchari Indian J. Chem. 4 1966 520
27. J. Strohmeier, and E. von Angerer Arch. Pharm. (Weinheim) 320 1987 407
28. 3H]estradiol. After 16 h at 4°C, dextran-coated charcoal (20 μL) was added. After 15 min at room temperature, the charcoal was removed by centrifugation and the radioactive ligand present in the supernatant was measured by scintillation counting. All reagents were obtained from Sigma (St. Louis, MO).
29. 2,3-Diphenyl Indole CAS # 3469-20-3. MP BioMedicals 15 Morgan, Irvine, CA 92618-2005.
30. G.M. Anstead, and K.E. Carlson J.A. Katzenellenbogen Steroids 62 1997 268
31. We used the Sybyl program (Tripos Associates, St. Louis, MO.) for docking structures 7c manually into the active sites of ER-α and ER-β crystal structures (pdb codes 1L2I,1QKM, respectively). The compounds were manually overlapped with the co-crystallized ligands and then allowed to relax in the active site of the protein using the Sybyl force field, Gasteiger-Huckel charges on the ligands, and Kollman All Atom charges on the protein. The phenolic substituents of each structure were held in place to mimic the phenolic substituents of the co-crystallized ligands. The resulting conformations were then used to analyze contact points between the protein and the ligand for the purpose of explaining potential selectivity differences in the active sites of ER-α and ER-β based on our predicated binding modes.
32. G. Mor, E. Sapi, V.M. Abrahams, T. Rutherford, J. Song, X.-Y. Hao, S. Muzaffer, and F. Kohen J. Immunol. 170 2003 114
33. M.L. O'Brien, K. Park, Y. In, and O.-K. Park-Sarge Endocrinology 140 1999 4530
34. B. del Rio, J.M.G. Pedrero, C. Martinez-Campa, P. Zuazuo, P.S. Lazo, and S. Ramos J. Biol. Chem. 279 2004 38294
35. Whole cell assays. Estrogenic activity in human breast cancer MCF7 cells and primary rat granulosa cells was assessed by transient transfection of an estrogen responsive ERE3-TK-lux luciferase reporter vector essentially as we have described previously in other cell backgrounds (Petersen et al.). The MCF7 cell activity was considered to be mediated through ER-α and the granulosa activity was considered to be mediated through ER-β. MCF7 cells were obtained from ATTC (Manassas, VA) and transfected with Lipofectamine Plus (Gibco/BRL, Rockville, MD), as described by the manufacturers. Luciferase activity was measured 24 h after the addition of compounds. D.N. Petersen, G.T. Tkalcevic, P.H. Koza-Taylor, T.G. Turi, and T.A. Brown Endocrinology 139 1998 1082